Johnson & Johnson to buy Crucell
J&J is in advanced plans to acquire the Dutch vaccine producer for $2.3 billion.
By Joseph Woelfel, TheStreet
J&J, which already owns 17.9% of Crucell, would acquire the rest for 1.75 billion euros ($2.3 billion), or 24.75 euros a share, in cash.
Crucell closed Thursday at 15.70 euros, making the intended offer a 58% premium.
Crucell makes vaccines and sells a line of cells widely used as a platform for developing vaccines.
The boards of J&J and Crucell have authorized the companies to proceed with the talks for a potential transaction.
The companies expect that Crucell's strength in the manufacturing, discovery and commercialization of vaccines would create a strong platform for J&J in vaccines, the companies said in a statement Friday.
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
[BRIEFING.COM] Unable to stage a significant rebound, the major averages continue to hover near their worst levels of the day. The S&P 500 trades lower by 0.6% with the energy sector leading to the downside.
The growth-sensitive group sports a loss of 0.9% amid weakness in crude oil. The energy component is off by 0.7% at $93.63 per barrel.
Elsewhere, the Dow Jones Transportation Average is a notable laggard as 19 of 20 components trade lower. As a result, the bellwether ... More
More Market News
|There’s a problem getting this information right now. Please try again later.|
LATEST MARKET DISPATCHES
- No more Dispatches; here's where to find market news
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
- Dow falls 59 as late-day gloom kills a rally
- Stocks held back by fiscal-cliff worries
- Stocks suffer worst weekly loss in 5 months
- Dow off 121 as post-election swoon continues
- Dow slumps 313 after Obama's re-election
- Dow jumps 133 as Americans head to the polls
Despite the lower stock price, it isn't the right time to take another bite. Here are 4 reasons why.